Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-2 of 2

Sort by

Sort Order Select

Journal Articles

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Paola Guglielmelli, MD, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Ming-hui Duan, MD, Haitao Meng, MD PhD, Ling Pan, MD PhD, Guangsheng He, MD PhD, Srdan Verstovsek, MD PhD, Françoise Boyer-Perrard, MD, Fiorenza Barraco, MD, Dietger Niederwieser, MD PhD, Anna Marina Liberati, MD, Claire Harrison, DM, FRCP, FRCPath, Pantelia Roussou, MSc, Monika Wroclawska, MD, Kevin Majidi, Peter AW te Boekhorst, MD PhD, Heinz Gisslinger, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137742

Published: 2020

Journal Articles

An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

Peter AW te Boekhorst, MD PhD, Alexandre Theocharides, MD, Heinz Gisslinger, MD, Timothy Devos, MD, Eric Lippert, MD PhD, Damianos Sotiropoulos, MD, Miklos Egyed, MD PhD, Valerio De Stefano, MD, Vincenzo Accurso, MD, Alessandra Iurlo, MD PhD, Anders E.A. Dahm, MD PhD, Regina Garcia-Delgado, MD, Nathan Cantoni, MD, Mike Zuurman, PhD, Michael Zaiac, MD, Erik Houtsma, MSc, Amir Iqbal, PhD, Paola Di Matteo, MD PhD, Alberto Alvarez-Larrán, MD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134210

Published: 2020